NCT01910870终止2 期
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
Centre Jean Perrin1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2013年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Response rate of cisplatin - metronomic cyclophosphamide treatment
研究概览
简要总结
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age > 18 ans,
- •Performance status < 2,
- •Patient with metastatic breast cancer stade IV triple negative histologically confirmed
- •Measurable or not disease but radiologically evaluable (RECIST 1.1),
- •Negative Hormonal Receptors (Estrogens and/or Progesterone), HER-2 negative (Score 0 or 1 by Immunochemistry (IHC), negative FISH if score IHC 2),
- •Patient with a progression during or after an anthracyclines and/or taxanes treatment receiving in neo-adjuvant or adjuvant regimen according to a resistance defined as a documented disease progression in the last 12 month after the last dose of taxanes or anthracyclines,
- •Patient non previously treated by platinum salts,
- •Hematological Functions: Neutrophiles ≥ 1,5.109/L, Platelets ≥ 100.109/L, Leucocytes > 3 000/mm3, Hb > 9g/dL,
- •Hepatic Functions : total Bilirubin ≤ 1,5 time upper normal value (UNV), ASAT ≤ 2 ,5 time UNV, ALAT ≤ 2,5 time UNV, Alkaline Phosphatase ≤ 2,5 time UNV (< 5 time UNV if case of hepatic metastasis),
- •Renal Functions: Creatinine Clearance ≥ 60 mL/min,
- •Patient signed the consent study form,
- •Patient affiliated to a social security regimen (law of 9 August 2004).
排除标准
- •Male Patients,
- •Unknown hormonal Receptors
- •Positive HER-2 (Score 3 in IHC or positive FISH)
- •Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant in the 6 months after the end of treatment,
- •Patient not using contraceptive treatment during the treatment or after the 6 months after the end of treatment,
- •Patient is a ward,
- •Patient suffering from a non compatible disease with the enrollment in the study,
- •Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) < 1 year before the study enrollment or randomisation,
- •Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2), meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).
- •Uncontrolled diabetes,
- •Psychiatric or neurological significant abnormality,
- •Peripheric Neuropathy > grade 2,
- •Antecedent of hypersensibility to one of study treatment or one of used excipients,
- •Urinary tract infection or acute hemorrhagic cystitis in progress
- •Concomitant treatment with a medicine containing phenytoin or medication received in the context of a trial, or participation in another therapeutic clinical trial within <30 days prior treatment with chemotherapy.
- •Geographically unstable patient in the next 6 months or remaining distance to the treatment center making it difficult to follow in the study,
- •Known history of abuse of narcotic or other drug or alcohol
- •History of surgery within 28 days before the start of treatment,
- •Patient unwilling or unable to comply with the requirements of the study.
研究组 & 干预措施
Cisplatin - Metronomic Cyclophosphamide
Experimental
Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
干预措施: Cisplatin (Drug)
Cisplatin - Metronomic Cyclophosphamide
Experimental
Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
干预措施: Metronomic Cyclophosphamide (Drug)
结局指标
主要结局
Response rate of cisplatin - metronomic cyclophosphamide treatment
时间窗: 18 months and 6 weeks
次要结局
- Disease free progression(3 years)
- safety profile of cisplatin - metronomic cyclophosphamide association(18 months and 6 weeks)
- Overall survival(5 years)
- Predictive factors to response and/or resistance treatment(18 months and 6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and TaxanesMetastatic Breast CancerNCT01910844Centre Jean Perrin3
撤回
2 期
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic MelanomaMetastatic MelanomaNCT01833767Western Regional Medical Center
进行中（未招募）
不适用
A Phase II study evaluating the role of the combination of cisplatin and cyclophosphamide administered metronomically in patients with advanced breast cancer triple negative (Estrogen and progesterone receptors negative and c-erb B2 non overexpressed).Advanced, triple receptor negative breast cancerMedDRA version: 14.1Level: PTClassification code 10055113Term: Breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-020835-38-ITISTITUTO EUROPEO DI ONCOLOGIA
终止
2 期
Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney TransplantsAntibody Mediated RejectionNCT01630538University of Manitoba4
终止
3 期
Treatment of Tumors of the Choroid Plexus EpitheliumChoroid Plexus TumorsNCT00500890M.D. Anderson Cancer Center2